share_log

华东医药(000963.SZ):子公司签署产品独家商业化合作协议

Huadong Medicine (000963.SZ): Subsidiary signed an exclusive commercial cooperation agreement for the product.

Gelonghui Finance ·  Aug 4 04:33

On August 2, 2024, Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine (stock code: 000963.SZ), signed an exclusive commercial cooperation agreement (the “Cooperation Agreement”) with Beijing Yimiao Shenzhou Medical Technology Co., Ltd. (referred to as “Yimiao Shenzhou”) to obtain the exclusive commercialization rights in the mainland China (hereinafter referred to as the “Licensed Area”) for the target CD19 autologous CAR-T candidate product IM19 chimeric antigen receptor T-cell injection (referred to as the “Licensed Product” or “Target Product”) developed by Yimiao Shenzhou. Huadong Medicine (Hangzhou) will pay Yimiao Shenzhou a down payment of CNY0.125 billion and a milestone payment for registration and sales not exceeding CNY0.95 billion.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment